<p>丹佛，2025 年 12 月 23 日（GLOBE NEWSWIRE）-- SeaStar Medical Holding Corporation（纳斯达克：ICU）是一家商业阶段的医疗保健公司，专注于改变面临器官衰竭和潜在生命危险的重症患者的治疗，今天宣布公司将进行 1 比 10 的反向股票拆分（Reverse Split），该拆分将于 2026 年 1 月 5 日东部时间凌晨 12:01 生效。公司的普通股将在 2026 年 1 月 5 日市场开盘时开始以拆分后调整的基础在纳斯达克资本市场（Nasdaq）交易。SeaStar Medical 的股票将继续以 “ICU” 的股票代码交易。</p>
<p>反向拆分的授权已于 2025 年 12 月 18 日在 SeaStar Medical 的 2025 年特别股东会议上获得公司股东的批准。反向拆分的目的是提高公司普通股的市场价格，以便使公司重新符合纳斯达克上市规则下的 1.00 美元最低出价价格要求。公司的普通股将以新的 CUSIP 号码进行交易 – 81256L302。</p>
<p>由于反向拆分，每 10 股拆分前的普通股将自动合并并转换为 1 股已发行和流通的普通股。记录在册的股东如果有权获得部分股份，将收到一整股普通股以替代该部分股份。反向拆分减少了因行使或归属其未发行股票期权和某些认股权证而可发行的普通股数量，按反向拆分的比例调整，并导致这些股票期权和认股权证的行使价格按比例上升。</p>
<p>记录在册的股东将在反向股票拆分后收到来自公司的过户代理人——大陆股票转让和信托公司（Continental Stock Transfer and Trust Company）关于其股份所有权的信息。大陆股票转让和信托公司可通过 800-509-8856 联系。通过银行、经纪人或其他代理持有股份的股东，其持仓将自动调整以反映反向拆分，无需在反向拆分中采取进一步行动，具体取决于经纪人的特定流程。</p>
<p>有关反向拆分的更多信息，请参阅 SeaStar Medical 于 2025 年 12 月 18 日向证券交易委员会提交的 8-K 表格当前报告。</p>
<p>关于 SeaStar Medical</p>
<p>SeaStar Medical 是一家商业阶段的医疗保健公司，专注于改变面临器官衰竭和潜在生命危险的重症患者的治疗。QUELIMMUNE（SCD-PED）疗法是 SeaStar Medical 基于其专利选择性细胞治疗设备（SCD）技术的首个商业产品。QUELIMMUNE（SCD-PED）疗法于 2024 年获得美国食品药品监督管理局（FDA）的批准。它是 FDA 批准的唯一针对因脓毒症或脓毒症状态导致的危及生命的急性肾损伤（AKI）在重症儿科患者中的超罕见病症的产品。SeaStar Medical 的选择性细胞治疗设备（SCD）疗法已获得 FDA 对六种治疗适应症的突破性设备认定，使其在批准和商业推出时具有更快速的审批路径和更有利的报销动态。该公司目前正在进行针对需要持续肾脏替代治疗（CRRT）的急性肾损伤（AKI）成年患者的 SCD 疗法的 NEUTRALIZE-AKI 关键试验，这是一种没有有效治疗方案的危及生命的疾病，每年影响美国超过 200,000 名成年人。</p>
<p>欲了解更多信息，请访问 www.seastarmedical.com 或在 LinkedIn 或 X 上关注我们。</p>
<p>前瞻性声明</p>
<p>本新闻稿包含根据 1955 年《私人证券诉讼改革法》“安全港” 条款的某些前瞻性声明。这些前瞻性声明包括但不限于，SeaStar Medical 对拟议的反向股票拆分的预期以及 SeaStar Medical 重新符合纳斯达克上市规则的能力。诸如 “相信”、“项目”、“期望”、“预期”、“估计”、“打算”、“战略”、“未来”、“机会”、“计划”、“可能”、“应该”、“将”、“会”、“将会”、“将继续”、“可能导致” 等类似表达旨在识别这些前瞻性声明。前瞻性声明是关于未来事件的预测、展望和其他声明，这些声明基于当前的期望和假设，因此，受到重大风险和不确定性的影响，这可能导致实际结果与预期结果存在重大差异。这些因素大多数超出了 SeaStar Medical 的控制范围，且难以预测。可能导致实际未来事件与预期结果存在重大差异的因素包括但不限于：(i) SeaStar Medical 可能无法获得其 SCD 产品候选者的监管批准的风险；(ii) SeaStar Medical 可能无法筹集足够资金以资助其运营，包括当前或未来的临床试验的风险；(iii) SeaStar Medical 及其当前和未来的合作伙伴无法成功开发和商业化其产品或服务，或在此过程中经历重大延迟，包括未能获得适用的联邦和州监管机构对其产品的批准的风险；(iv) SeaStar Medical 可能永远无法实现或维持盈利的风险；(v) SeaStar Medical 可能无法以可接受的条款获得额外融资的风险；(vi) 第三方供应商和制造商无法完全及时履行其义务的风险；(vii) 与 SeaStar Medical 的产品和服务相关的产品责任或监管诉讼或程序的风险；(viii) SeaStar Medical 无法确保或保护其知识产权的风险；以及 (ix) SeaStar Medical 在其 10-K 表格的年度报告中不时指出的其他风险和不确定性，包括 “风险因素” 部分及 SeaStar Medical 向 SEC 提交的其他文件中的内容。上述因素清单并不详尽。前瞻性声明仅在作出之日有效。读者被提醒不要过度依赖前瞻性声明，SeaStar Medical 不承担任何义务，也不打算更新或修订这些前瞻性声明，无论是由于新信息、未来事件还是其他原因。</p>
<p>联系方式：</p>
<p>IR@SEASTARMED.COM</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qYzROQ00zTXpNMU1qazNJekl5T1RrMU16TT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qYzROQ00zTXpNMU1qazNJekl5T1RrMU16TT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmViNWQ1MTAtYTZkYi00MmZiLTg3YTEtMTNmZWYyMzMwOGM1LTEzMTEwODMtMjAyNS0xMi0yMy1lbg==/tiny/SeaStar-Medical.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmViNWQ1MTAtYTZkYi00MmZiLTg3YTEtMTNmZWYyMzMwOGM1LTEzMTEwODMtMjAyNS0xMi0yMy1lbg==/tiny/SeaStar-Medical.png"/></p>

<p>SeaStar Medical 宣布将于 2026 年 1 月 5 日实施 1 比 10 的反向股票拆分，以重新符合纳斯达克 1.00 美元的最低报价要求。股票将以新的 CUSIP 编号 81256L302 进行交易，但保留股票代码 "ICU"。股东在 2025 年 12 月 18 日的特别会议上批准了此次拆分。零碎股份将被四舍五入为整股。此次拆分将按比例影响股票期权和认股权证</p>

<p>DENVER, Dec. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today the Company’s 1-for-10 reverse stock split (Reverse Split), which will become effective as of 12:01 a.m. Eastern Time on January 5, 2026. The Company’s common stock will begin trading on a post-split adjusted basis on The Nasdaq Capital Market (Nasdaq) effective with the open of the market on January 5, 2026. SeaStar Medical’s stock will continue to trade under the ticker symbol “ICU.”</p>
<div class="lb-trans"><p>丹佛，2025 年 12 月 23 日（GLOBE NEWSWIRE）-- SeaStar Medical Holding Corporation（纳斯达克：ICU）是一家商业阶段的医疗保健公司，专注于改变面临器官衰竭和潜在生命危险的重症患者的治疗，今天宣布公司将进行 1 比 10 的反向股票拆分（Reverse Split），该拆分将于 2026 年 1 月 5 日东部时间凌晨 12:01 生效。公司的普通股将在 2026 年 1 月 5 日市场开盘时开始以拆分后调整的基础在纳斯达克资本市场（Nasdaq）交易。SeaStar Medical 的股票将继续以 “ICU” 的股票代码交易。</p>
</div><p>Authorization for the Reverse Split was approved by the Company’s stockholders at SeaStar Medical’s 2025 Special Meeting of Stockholders held on December 18, 2025. The objective of the Reverse Split is to increase the market price for the Company’s common stock to, among things, enable the Company to regain compliance with the $1.00 minimum bid price requirement under applicable Nasdaq Listing Rules. The Company's common stock will trade under a new CUSIP number – 81256L302.</p>
<div class="lb-trans"><p>反向拆分的授权已于 2025 年 12 月 18 日在 SeaStar Medical 的 2025 年特别股东会议上获得公司股东的批准。反向拆分的目的是提高公司普通股的市场价格，以便使公司重新符合纳斯达克上市规则下的 1.00 美元最低出价价格要求。公司的普通股将以新的 CUSIP 号码进行交易 – 81256L302。</p>
</div><p>As a result of the Reverse Split, each 10 pre-split shares of common stock outstanding will automatically combine and convert to 1 issued and outstanding share of common stock. Stockholders of record who otherwise would be entitled to receive fractional shares will receive one whole share of common stock in lieu of such fractional share. The Reverse Split reduces the number of shares of common stock issuable upon the exercise or vesting of its outstanding stock options and certain warrants in proportion to the ratio of the Reverse Split and causes a proportionate increase in the exercise prices of such stock options and warrants.</p>
<div class="lb-trans"><p>由于反向拆分，每 10 股拆分前的普通股将自动合并并转换为 1 股已发行和流通的普通股。记录在册的股东如果有权获得部分股份，将收到一整股普通股以替代该部分股份。反向拆分减少了因行使或归属其未发行股票期权和某些认股权证而可发行的普通股数量，按反向拆分的比例调整，并导致这些股票期权和认股权证的行使价格按比例上升。</p>
</div><p>Stockholders of record will receive information regarding their share ownership following the reverse stock split from the Company’s transfer agent, Continental Stock Transfer and Trust Company. Continental Stock Transfer and Trust Company can be reached at 800-509-8856. Stockholders owning shares via a bank, broker or other nominee will have their positions automatically adjusted to reflect the Reverse Split and will not be required to take further action in connection with the Reverse Split, subject to brokers’ particular processes.</p>
<div class="lb-trans"><p>记录在册的股东将在反向股票拆分后收到来自公司的过户代理人——大陆股票转让和信托公司（Continental Stock Transfer and Trust Company）关于其股份所有权的信息。大陆股票转让和信托公司可通过 800-509-8856 联系。通过银行、经纪人或其他代理持有股份的股东，其持仓将自动调整以反映反向拆分，无需在反向拆分中采取进一步行动，具体取决于经纪人的特定流程。</p>
</div><p>For additional information regarding the Reverse Split, please refer to SeaStar Medical’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 18, 2025.</p>
<div class="lb-trans"><p>有关反向拆分的更多信息，请参阅 SeaStar Medical 于 2025 年 12 月 18 日向证券交易委员会提交的 8-K 表格当前报告。</p>
</div><p>About SeaStar Medical</p>
<div class="lb-trans"><p>关于 SeaStar Medical</p>
</div><p>SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. The QUELIMMUNE (SCD-PED) therapy was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.</p>
<div class="lb-trans"><p>SeaStar Medical 是一家商业阶段的医疗保健公司，专注于改变面临器官衰竭和潜在生命危险的重症患者的治疗。QUELIMMUNE（SCD-PED）疗法是 SeaStar Medical 基于其专利选择性细胞治疗设备（SCD）技术的首个商业产品。QUELIMMUNE（SCD-PED）疗法于 2024 年获得美国食品药品监督管理局（FDA）的批准。它是 FDA 批准的唯一针对因脓毒症或脓毒症状态导致的危及生命的急性肾损伤（AKI）在重症儿科患者中的超罕见病症的产品。SeaStar Medical 的选择性细胞治疗设备（SCD）疗法已获得 FDA 对六种治疗适应症的突破性设备认定，使其在批准和商业推出时具有更快速的审批路径和更有利的报销动态。该公司目前正在进行针对需要持续肾脏替代治疗（CRRT）的急性肾损伤（AKI）成年患者的 SCD 疗法的 NEUTRALIZE-AKI 关键试验，这是一种没有有效治疗方案的危及生命的疾病，每年影响美国超过 200,000 名成年人。</p>
</div><p>For more information visit www.seastarmedical.com or visit us on LinkedIn or X.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.seastarmedical.com 或在 LinkedIn 或 X 上关注我们。</p>
</div><p>Forward-Looking Statements</p>
<div class="lb-trans"><p>前瞻性声明</p>
</div><p>This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect to the proposed reverse stock split and the ability of SeaStar Medical to regain compliance with Nasdaq listing rules. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to secure additional financing on acceptable terms; (vi) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1955 年《私人证券诉讼改革法》“安全港” 条款的某些前瞻性声明。这些前瞻性声明包括但不限于，SeaStar Medical 对拟议的反向股票拆分的预期以及 SeaStar Medical 重新符合纳斯达克上市规则的能力。诸如 “相信”、“项目”、“期望”、“预期”、“估计”、“打算”、“战略”、“未来”、“机会”、“计划”、“可能”、“应该”、“将”、“会”、“将会”、“将继续”、“可能导致” 等类似表达旨在识别这些前瞻性声明。前瞻性声明是关于未来事件的预测、展望和其他声明，这些声明基于当前的期望和假设，因此，受到重大风险和不确定性的影响，这可能导致实际结果与预期结果存在重大差异。这些因素大多数超出了 SeaStar Medical 的控制范围，且难以预测。可能导致实际未来事件与预期结果存在重大差异的因素包括但不限于：(i) SeaStar Medical 可能无法获得其 SCD 产品候选者的监管批准的风险；(ii) SeaStar Medical 可能无法筹集足够资金以资助其运营，包括当前或未来的临床试验的风险；(iii) SeaStar Medical 及其当前和未来的合作伙伴无法成功开发和商业化其产品或服务，或在此过程中经历重大延迟，包括未能获得适用的联邦和州监管机构对其产品的批准的风险；(iv) SeaStar Medical 可能永远无法实现或维持盈利的风险；(v) SeaStar Medical 可能无法以可接受的条款获得额外融资的风险；(vi) 第三方供应商和制造商无法完全及时履行其义务的风险；(vii) 与 SeaStar Medical 的产品和服务相关的产品责任或监管诉讼或程序的风险；(viii) SeaStar Medical 无法确保或保护其知识产权的风险；以及 (ix) SeaStar Medical 在其 10-K 表格的年度报告中不时指出的其他风险和不确定性，包括 “风险因素” 部分及 SeaStar Medical 向 SEC 提交的其他文件中的内容。上述因素清单并不详尽。前瞻性声明仅在作出之日有效。读者被提醒不要过度依赖前瞻性声明，SeaStar Medical 不承担任何义务，也不打算更新或修订这些前瞻性声明，无论是由于新信息、未来事件还是其他原因。</p>
</div><p>Contact:</p>
<div class="lb-trans"><p>联系方式：</p>
</div><p>IR@SEASTARMED.COM</p>
<div class="lb-trans"><p>IR@SEASTARMED.COM</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qYzROQ00zTXpNMU1qazNJekl5T1RrMU16TT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNjc4NCM3MzM1Mjk3IzIyOTk1MzM="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmViNWQ1MTAtYTZkYi00MmZiLTg3YTEtMTNmZWYyMzMwOGM1LTEzMTEwODMtMjAyNS0xMi0yMy1lbg==/tiny/SeaStar-Medical.png" alt="" original-src="https://ml.globenewswire.com/media/MmViNWQ1MTAtYTZkYi00MmZiLTg3YTEtMTNmZWYyMzMwOGM1LTEzMTEwODMtMjAyNS0xMi0yMy1lbg==/tiny/SeaStar-Medical.png"/></p>

SeaStar Medical 宣布进行 1 比 10 的反向拆股 | ICU 股票新闻